HelixBind awarded grant from CARB-X to accelerate development of culture-free test for bloodstream:
MARLBOROUGH, Mass., March 15, 2018 /PRNewswire/ -- HelixBind, Inc. announced a collaboration with CARB-X, (Combating Antibiotic Resistant Bacteria Accelerator), a global partnership funding the development of promising new antibacterial products and diagnostics. The company is eligible to receive up to $2 million based on certain milestones supporting the development of a test for bloodstream infections on the company's proprietary RaPID diagnostic platform.
No comments:
Post a Comment